James E Flynn Insider Trading $FIXX Homology Medicines, Inc.
Get free email notifications about insider trading for James E Flynn.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of James E Flynn. James E Flynn is 10% Owner in CAS MEDICAL SYSTEMS INC ($CAMY.OB) and 10% Owner in AxoGen, Inc. ($LECT) and 10% Owner in PAR PHARMACEUTICAL COMPANIES, INC. ($PRX) and 10% Owner in Fibrocell Science, Inc. ($FCSC) and 10% Owner in STREAMLINE HEALTH SOLUTIONS INC. ($LANV) and 10% Owner in ANTARES PHARMA, INC. ($ATRS) and 10% Owner in VIA Pharmaceuticals, Inc. ($CAQ) and 10% Owner in DUSA PHARMACEUTICALS INC ($DUSA) and 10% Owner in HI TECH PHARMACAL CO INC ($HITK) and 10% Owner in AVADEL PHARMACEUTICALS PLC ($AVDL) and 10% Owner in INSPIRE PHARMACEUTICALS INC ($ISPH) and 10% Owner in RIGEL PHARMACEUTICALS INC ($RIGL) and 10% Owner in ARENA PHARMACEUTICALS INC ($ARNA) and 10% Owner in ISTA PHARMACEUTICALS INC ($ISTA) and 10% Owner in MEDICINES CO /DE ($MDCO) and 10% Owner in THIRD WAVE TECHNOLOGIES INC /WI ($TWTI) and 10% Owner in DYNAVAX TECHNOLOGIES CORP ($DVAX) and 10% Owner in Cyclacel Pharmaceuticals, Inc. ($CYCC) and Director in Talon Therapeutics, Inc. ($EMLR) and 10% Owner in LUMOS PHARMA, INC. ($NLNK) and 10% Owner in NITROMED INC ($NTMD) and 10% Owner in XENOPORT INC ($XNPT) and 10% Owner in EMAGEON INC ($EMAG) and 10% Owner in CATALYST BIOSCIENCES, INC. ($CBIO) and 10% Owner in ALIMERA SCIENCES INC ($ALIM) and 10% Owner in NeuroMetrix, Inc. ($NURO) and 10% Owner in NxStage Medical, Inc. ($NXTM) and 10% Owner in aTYR PHARMA INC ($LIFE) and 10% Owner in Vanda Pharmaceuticals Inc. ($VNDA) and 10% Owner in XERIS PHARMACEUTICALS INC ($XERS) and Director in PROTEON THERAPEUTICS INC ($PRTO) and 10% Owner in eHealth, Inc. ($EHTH) and 10% Owner in ZAFGEN, INC. ($ZFGN) and 10% Owner in NeurogesX Inc ($NGSX) and 10% Owner in Invuity, Inc. ($IVTY) and 10% Owner in Dicerna Pharmaceuticals Inc ($DRNA) and 10% Owner in CONSTELLATION PHARMACEUTICALS INC ($CNST) and 10% Owner in TriVascular Technologies, Inc. ($TRIV) and 10% Owner in Auspex Pharmaceuticals, Inc. ($ASPX) and 10% Owner in Neos Therapeutics, Inc. ($NEOS) and 10% Owner in Schrodinger, Inc. ($SDGR) and 10% Owner in CytomX Therapeutics, Inc. ($CTMX) and Director in Acutus Medical, Inc. ($AFIB) and 10% Owner in Annexon, Inc. ($ANNX) and 10% Owner in Aclaris Therapeutics, Inc. ($ACRS) and 10% Owner in Syros Pharmaceuticals, Inc. ($SYRS) and 10% Owner in Mallinckrodt plc ($MNK) and 10% Owner in Loxo Oncology, Inc. ($LOXO) and 10% Owner in Adverum Biotechnologies, Inc. ($AAVL) and 10% Owner in REGENXBIO Inc. ($RGNX) and 10% Owner in Recro Pharma, Inc. ($REPH) and 10% Owner in Nivalis Therapeutics, Inc. ($NVLS) and Director in Nivalis Therapeutics, Inc. ($NVLS) and 10% Owner in Audentes Therapeutics, Inc. ($BOLD) and 10% Owner in SteadyMed Ltd. ($STDY) and 10% Owner in ShockWave Medical, Inc. ($SWAV) and 10% Owner in RHYTHM PHARMACEUTICALS, INC. ($RYTM) and 10% Owner in Editas Medicine, Inc. ($EDIT) and Director in AveXis, Inc. ($AVXS) and 10% Owner in ARVINAS INC. ($ARVN) and 10% Owner in Homology Medicines, Inc. ($FIXX) and Director in Homology Medicines, Inc. ($FIXX) and Director in Oncorus, Inc. ($ONCR) and 10% Owner in Revolution Medicines, Inc. ($RVMD) and 10% Owner in Black Diamond Therapeutics, Inc. ($BDTX) and 10% Owner in Frequency Therapeutics, Inc. ($FREQ) and Director in DFB Healthcare Acquisitions Corp. ($DFBH) and 10% Owner in Generation Bio Co. ($GBIO) and 10% Owner in Kiniksa Pharmaceuticals, Ltd. ($KNSA) and 10% Owner in Mirum Pharmaceuticals, Inc. ($MIRM) and 10% Owner in Cabaletta Bio, Inc. ($CABA) and 10% Owner in Werewolf Therapeutics, Inc. ($HOWL) and 10% Owner in Nkarta, Inc. ($NKTX) and 10% Owner in Edgewise Therapeutics, Inc. ($EWTX) and Director in DFP HEALTHCARE ACQUISITIONS CORP. ($DFPH) and Director in Deerfield Healthcare Technology Acquisitions Corp. ($DFHT) and 10% Owner in Terns Pharmaceuticals, Inc. ($TERN).
James E Flynn in Homology Medicines, Inc.
Trading Symbol: FIXXIndustry: PHARMACEUTICAL PREPARATIONS [2834]
Position of James E Flynn: 10% Owner, Director
Holdings: 509,970 shares
Latest Transaction: Jan 31 2020
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of James E Flynn in Homology Medicines, Inc.
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ACRS, AFIB, DFBH, ADVM, ALIM, ALPN, ANNX, ATRS, ARNA, ARVN, LIFE, BOLD, ASPX, AVDL, AVXS, LECT, BDTX, CABA, CAMY.OB, CBIO, CNST, CYCC, CTMX, DFHTW, DFPHU, DRNA, DUSA, DVAX, EWTX, EDIT, EHTH, EMAG, FCSC, FREQ, GBIO, HITK, FIXX, ISPH, IVTY, ISTA, KNSA, LRMR, LOXO, NLNK, MNK, MDCO, MIRM, NEOS, NGSX, NURO, NTMD, NKTX, NXTM, ONCR, PRX, TARA, REPH, RGNX, RVMD, RYTM, RIGL, SDGR, SWAV, STDY, LANV, SYRS, EMLR, TERN, TWTI, TRIV, VNDA, CAQ, HOWL, XNPT, XERS
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jan 31 2020 | FIXX | Homology Medicines ... | Flynn James E | 10% Owner | Sell | S | 15.45 | 509,970 | 7,879,037 | 0 | 510 K to 0 (-100.00 %) |
Jan 31 2020 | FIXX | Homology Medicines ... | Flynn James E | 10% Owner | Sell | S | 15.45 | 8,857 | 136,808 | 509,970 | 518.8 K to 510 K (-1.71 %) |
Jan 28 2020 | FIXX | Homology Medicines ... | Flynn James E | 10% Owner | Sell | S | 15.51 | 65,891 | 1,021,936 | 518,827 | 584.7 K to 518.8 K (-11.27 %) |
Jan 28 2020 | FIXX | Homology Medicines ... | Flynn James E | 10% Owner | Sell | S | 15.77 | 193,359 | 3,049,600 | 584,718 | 778.1 K to 584.7 K (-24.85 %) |
Jan 28 2020 | FIXX | Homology Medicines ... | Flynn James E | 10% Owner | Sell | S | 15.69 | 380,256 | 5,965,000 | 778,077 | 1.2 M to 778.1 K (-32.83 %) |
Dec 27 2019 | FIXX | Homology Medicines ... | Flynn James E | 10% Owner | Sell | S | 21.95 | 151,233 | 3,319,579 | 1,766,106 | 1.9 M to 1.8 M (-7.89 %) |
Dec 27 2019 | FIXX | Homology Medicines ... | Flynn James E | 10% Owner | Sell | S | 21.95 | 198,767 | 4,362,956 | 2,321,199 | 2.5 M to 2.3 M (-7.89 %) |
Dec 23 2019 | FIXX | Homology Medicines ... | Flynn James E | 10% Owner | Sell | S | 21.83 | 56,595 | 1,235,435 | 1,917,339 | 2 M to 1.9 M (-2.87 %) |
Dec 23 2019 | FIXX | Homology Medicines ... | Flynn James E | 10% Owner | Sell | S | 21.83 | 74,384 | 1,623,758 | 2,519,966 | 2.6 M to 2.5 M (-2.87 %) |
Dec 23 2019 | FIXX | Homology Medicines ... | Flynn James E | 10% Owner | Sell | S | 21.50 | 9,130 | 196,297 | 1,973,934 | 2 M to 2 M (-0.46 %) |
Dec 23 2019 | FIXX | Homology Medicines ... | Flynn James E | 10% Owner | Sell | S | 21.50 | 11,999 | 257,981 | 2,594,350 | 2.6 M to 2.6 M (-0.46 %) |
Dec 23 2019 | FIXX | Homology Medicines ... | Flynn James E | 10% Owner | Sell | S | 21.68 | 5,454 | 118,219 | 1,983,064 | 2 M to 2 M (-0.27 %) |
Dec 23 2019 | FIXX | Homology Medicines ... | Flynn James E | 10% Owner | Sell | S | 21.68 | 7,168 | 155,371 | 2,606,349 | 2.6 M to 2.6 M (-0.27 %) |
Dec 23 2019 | FIXX | Homology Medicines ... | Flynn James E | 10% Owner | Sell | S | 21.83 | 56,595 | 1,235,435 | 1,917,339 | 2 M to 1.9 M (-2.87 %) |
Dec 23 2019 | FIXX | Homology Medicines ... | Flynn James E | 10% Owner | Sell | S | 21.83 | 74,384 | 1,623,758 | 2,519,966 | 2.6 M to 2.5 M (-2.87 %) |
Dec 23 2019 | FIXX | Homology Medicines ... | Flynn James E | 10% Owner | Sell | S | 21.50 | 9,130 | 196,297 | 1,973,934 | 2 M to 2 M (-0.46 %) |
Dec 23 2019 | FIXX | Homology Medicines ... | Flynn James E | 10% Owner | Sell | S | 21.50 | 11,999 | 257,981 | 2,594,350 | 2.6 M to 2.6 M (-0.46 %) |
Dec 23 2019 | FIXX | Homology Medicines ... | Flynn James E | 10% Owner | Sell | S | 21.68 | 5,454 | 118,219 | 1,983,064 | 2 M to 2 M (-0.27 %) |
Dec 23 2019 | FIXX | Homology Medicines ... | Flynn James E | 10% Owner | Sell | S | 21.68 | 7,168 | 155,371 | 2,606,349 | 2.6 M to 2.6 M (-0.27 %) |
Jun 11 2019 | FIXX | Homology Medicines ... | Flynn James E | Director | Option Exercise | A | 19.51 | 15,580 | 303,966 | 15,580 | |
Apr 15 2019 | FIXX | Homology Medicines ... | Flynn James E | Director | Buy | P | 22.50 | 533,333 | 11,999,993 | 1,158,333 | 625 K to 1.2 M (+85.33 %) |
Apr 04 2018 | FIXX | Homology Medicines ... | Flynn James E | Director | Option Exercise | C | 0.00 | 6,944,444 | 0 | 0 | |
Apr 04 2018 | FIXX | Homology Medicines ... | Flynn James E | Director | Option Exercise | C | 0.00 | 6,944,445 | 0 | 0 | |
Apr 04 2018 | FIXX | Homology Medicines ... | Flynn James E | Director | Option Exercise | C | 0.00 | 3,521,126 | 0 | 0 | |
Apr 04 2018 | FIXX | Homology Medicines ... | Flynn James E | Director | Option Exercise | C | 0.00 | 3,521,126 | 0 | 0 | |
Apr 04 2018 | FIXX | Homology Medicines ... | Flynn James E | Director | Buy | P | 16.00 | 625,000 | 10,000,000 | 625,000 | 0 to 625 K |
Apr 04 2018 | FIXX | Homology Medicines ... | Flynn James E | Director | Buy | P | 16.00 | 625,000 | 10,000,000 | 2,613,517 | 2 M to 2.6 M (+31.43 %) |
Apr 04 2018 | FIXX | Homology Medicines ... | Flynn James E | Director | Buy | C | 0.00 | 1,319,483 | 0 | 1,988,517 | 669 K to 2 M (+197.22 %) |
Apr 04 2018 | FIXX | Homology Medicines ... | Flynn James E | Director | Buy | C | 0.00 | 1,319,484 | 0 | 1,988,518 | 669 K to 2 M (+197.22 %) |
Apr 04 2018 | FIXX | Homology Medicines ... | Flynn James E | Director | Buy | C | 0.00 | 669,034 | 0 | 669,034 | 0 to 669 K |
Apr 04 2018 | FIXX | Homology Medicines ... | Flynn James E | Director | Buy | C | 0.00 | 669,034 | 0 | 669,034 | 0 to 669 K |
Mar 29 2018 | FIXX | Homology Medicines ... | Flynn James E | Director | Option Exercise | A | 16.00 | 31,160 | 498,560 | 31,160 |
Page: 1